Auro Laboratories

Auro Laboratories P/FCF

The P/FCF (Price-to-Free-Cash-Flow Ratio) of Auro Laboratories (530233.BO) as of Oct 19, 2026 is -13.06. In the previous year, P/FCF (Price-to-Free-Cash-Flow Ratio) was -9.43 — a change of 38.50% (lower).

P/FCF

-13.06

YoY

38.50%

Last updated:

P/FCF (Price-to-Free-Cash-Flow Ratio) of Auro Laboratories is 2026 -13.06 . P/FCF (Price-to-Free-Cash-Flow Ratio) of Auro Laboratories was 2025 -9.43 . It decreases by 38.50% lower compared to the previous year.

The Auro Laboratories P/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/FCF
Date
P/FCF
Jan 1, 2019
32.39 INR
Jan 1, 2020
19.99 INR
Jan 1, 2021
13.68 INR
Jan 1, 2022
-15.20 INR
Jan 1, 2023
-214.66 INR
Jan 1, 2024
-10.11 INR
Jan 1, 2025
-9.43 INR
Jan 1, 2026
-13.06 INR
The Auro Laboratories P/FCF history
YEARP/FCFYoY
-13.06+38.50%
-9.43-6.76%
-10.11-95.29%
-214.66+1,312.19%
-15.20-211.08%
13.68-31.54%
19.99-38.29%
32.39-19.10%
40.04+14.30%
35.03+10.25%
31.77-129.00%
-109.56-348.52%
44.08—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Auro Laboratories Stock analysis

What does Auro Laboratories do? Auro Laboratories Ltd is a pharmaceutical company headquartered in Mumbai, India. The company engages in the manufacture of active pharmaceutical ingredients (APIs), intermediates, and generic formulations. It operates primarily within the Pharmaceuticals sector. Auro Laboratories offers APIs across various therapeutic categories, including antihistamines, muscle relaxants, diuretics, iron deficiency treatments, anti-diabetics, anti-fungals, anti-ulcer medications, iodine supplements, anti-malarials, analgesics, antacids, and anti-inflammatories. The company also produces intermediates such as Glibenclamide Sulphonamide, Cis-bromo benzoate, Cls-Tosylate, 2-Ethoxy Benzoic Acid, 3,4,5-Trimethoxy Benzoic Acid, and 5-Bromo Phthalide. Additionally, Auro Laboratories provides toll and custom manufacturing services for APIs and intermediates on a contract basis. The company has an international presence, with a significant portion of its production exported to Southeast Asia, the Middle East, and various European countries. Key export destinations include Egypt, Germany, Malaysia, Singapore, South Africa, Brazil, Spain, and the United Kingdom. Auro Laboratories went public with its IPO on March 7, 1995. The company's website is http://www.aurolabs.com/. Auro Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Auro Laboratories stock

P/FCF (Price-to-Free-Cash-Flow Ratio) of Auro Laboratories is -13.06 in 2026.

P/FCF (Price-to-Free-Cash-Flow Ratio) of Auro Laboratories changed from -9.43 to -13.06, representing a 38.50% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/FCF (Price-to-Free-Cash-Flow Ratio) Auro Laboratories since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Free-Cash-Flow ratio measures how much investors pay for each unit of free cash flow. A lower ratio may indicate better value.

P/FCF = Market Capitalization / Free Cash Flow

To evaluate P/FCF (Price-to-Free-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/FCF (Price-to-Free-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/FCF (Price-to-Free-Cash-Flow Ratio)'s Auro Laboratories with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Auro Laboratories

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Auro Laboratories